Sentences with phrase «of lung cancer treatment»
«Immunotherapy data heralds new era of lung cancer treatment.»
https://www.sciencedaily.com/
A blood pressure drug may make a type of lung cancer treatment more effective, suggests a new study.
«Blood pressure drug may boost effectiveness of lung cancer treatment.»
Not exact matches
This drug has already staked its claim in the world of next - gen «checkpoint inhibitor» cancer treatments by besting rival Bristol - Myers Squibb's competing treatment Opdivo in advanced non-small cell lung cancer (NSCLC).
At 55 years old, Carol Cesario's stage IV lung cancer treatments induced hallucinations of Jon Bon Jovi, a rock star she's loved since the»80s.
Merck R&D chief Roger Perlmutter said his company believes the Keynote - 024 results «have the potential to change the therapeutic paradigm in first - line treatment of non-small-cell lung cancer.»
The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.
«What is particularly encouraging is that we are now able to select, based on features in the tumor, approximately a quarter of advanced lung cancer patients who can receive immunotherapy as their initial treatment.
«One of the toughest challenges of lung cancer is what to do for patients when the cancer comes back in an area that's been treated previously with radiation treatment,» said James J. Urbanic, M.D., lead author of the studies and a radiation oncologist at Wake Forest Baptist.
Aaron P. Mitchell, M.D., of the University of North Carolina at Chapel Hill School of Medicine, and coauthors examined FCOIs during 2014 among 125 authors of the guidelines for the treatment of breast, colon, prostate and lung cancer because those are the cancers with the highest incidence in the U.S.
Approximately one year after successful treatment with cytotoxic chemotherapy and radiotherapy, patients with advanced Small Cell Lung Cancer (SCLC), which primarily affects heavy smokers, generally relapse with recurrence of tumours that are resistant to further chemotherapy.
If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»
It's just a very different time now,» he said of the progress being made in the treatment of lung cancer.
Pembrolizumab, or pembro, an immunotherapy drug that unmasks cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arcancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, ArCancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.
Unfortunately, the treatment had little effect on the survival of the terminally ill lung cancer patients in the first trial.
«There has been a tremendous effort over the past several years to block EGFR as a treatment for lung cancer, but this therapy only works in a small subset of patients.
«Blocking both of these proteins could be a treatment that is beneficial for the majority of lung cancer patients,» said Dr. Habib, Associate Professor of Neurology and Neurotherapeutics with UT Southwestern's Peter O'Donnell Jr..
«We urgently need new treatments for lung cancer patients, and this research suggests we can boost the effectiveness of an existing drug, rather than switch to another new expensive treatment.
The trial also recorded fewer cases of lung cancer in those on the treatment, consistent with basic research findings hinting that the same inflammatory pathway may initiate or spur tumor growth.
A one - two combo punch using two currently available drugs could be an effective treatment for the majority of lung cancers, a study by scientists with UT Southwestern's Simmons Cancer Center shows.
Compared to a control (left), epalrestat treatment (right) reduces the number of metastatic tumors (arrowheads) in the lungs of mice injected with human basal - like breast cancer cells.
Called the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) and funded by the drug giant Novartis, the trial also found fewer cases of lung cancer in those on the treatment, rekindling basic research findings hinting that the same inflammatory pathway may initiate or spur the growth of such tumors.
«Although some non-small cell lung cancer patients have increased benefit of targeted therapy or immunotherapy instead of chemotherapy, for some groups of patients with NSNSCLC, chemotherapy has been the standard treatment for more than 30 years,» Gandhi notes.
This pre-clinical study from Professor Mazzone and his colleagues reveals a new molecular axis that may offer interesting therapeutic opportunities for the treatment of pancreatic cancer, breast cancer and lung cancer, among others.
Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option.
Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.
Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.
Few existing treatments offer durable survival benefits for patients whose NSCLC has spread past the lungs, due in part to the aggressive nature of lung cancer and its propensity to progress, even following treatment.
Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.
Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD - L1 expression, according to the results of the phase III KEYNOTE - 024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.
Now doctors have investigated the use of crizotinib in patients with ALK positive lung cancer who have not yet received any chemotherapy treatment.
P: We found discodermolide [a drug from Discodermia, a sponge found in the Caribbean, the Bahamas, and the Gulf of Mexico], and it's gone through phase I clinical trials for treatment of solid tumors such as ovarian, pancreatic, breast, colon, or lung cancers.
In the group that received targeted treatment for ALK - positive lung cancer, each category of tumor reduction was associated with corresponding gains in PFS and OS.
«This study demonstrates the value of testing lung cancer tissue for an ALK rearrangement, and it underscores the potential of cancer genomics to target cancer treatments to each patient,» says the study's senior author, Pasi A. Jänne, MD, PhD, who is the director of the Lowe Center for Thoracic Oncology of Dana - Farber.
«First - line immunotherapy treatment can improve survival for subset of lung cancer patients: Results of phase III global clinical trial show that 75 percent of stage IV lung cancer patients with both complex tumor mutations and PDL - 1 positive status respond to nivolumab.»
Your special report on the treatment of lung cancer (30 June, p 6) is very illuminating.
Right now, the tests, which are available from several companies, mostly aid in treatment decisions for people already diagnosed with a particular form of cancer, such as prostate or lung.
Treatments for diabetes, smoking, Alzheimer's disease and lung cancer are just a few of the potentially lifesaving cures Scientific American has chosen to highlight in this year's roundup of drugs you've never heard of, despite their potentially huge impact on global health.
«We're just beginning to understand the relevance of airway field cancerization to lung cancer detection and development of treatment and prevention strategies,» Kadara said.
The authors found that most lung cancer patients (regardless of stage) want physical activity advice directly from a physician at a cancer center before cancer treatment and exercise guidance may increase compliance with a dedicated program.
Moving forward, they plan to continue testing derivatives of HIPP for the treatment of colon cancer and also see if their findings extend to breast, lung, ovarian and prostate cancers.
A new drug that targets not only common cancer - causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I / II clinical trial.
Biopsies of pulmonary lesions are essential for increasing the accuracy of diagnosis and treatment for respiratory illnesses such as lung cancer.
Other factors that increased suicide risk were being older, being widowed, refusing surgical treatment and having a difficult - to - treat (metastatic) type of lung cancer.
Clinical trials found that it is safe to regularly infuse brain and lung cancer patients with 800 — 1000 times the daily recommended amount of vitamin C as a potential strategy to improve outcomes of standard cancer treatments.
«For about 80 percent of our patients with lung cancer, we don't have tests like [the one for] ALK to tell us what treatments will work best,» Shaw says.
This poor performance is sadly typical for lung cancer treatments: Most are effective for between 3 and 15 percent of patients.
Susan Galbraith, head of the oncology innovative medicines unit at AstraZeneca, said: «Lung cancer is still the leading cancer killer, and we are working on a number of potential treatment options that could provide patients with a better chance of beating the disease.
The treatment is promising enough that research teams around the world are developing similar stem cell therapies that can target and eradicate cancers of the prostate, lung, breast, skin and other tissues.
«Some had failed multiple lines of treatment and were very, very sick, with advanced - stage lung cancer,» Shaw says.